Clinical trial · Interventional
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Liver Cancer Institiute ,Fudan University
NCT03642561CI-TRIAL-00046238unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiotherapy ablation | Device | — | UNRESOLVED |
| transarterial chemoembolization(TACE) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- RFA group
- description
- Patients in RFA group will accept RFA treatment
- interventionNames
- Device: radiotherapy ablation
- type
- ACTIVE_COMPARATOR
- label
- TACE group
- description
- Patients in TACE group will accept TACE treatment
- interventionNames
- Device: transarterial chemoembolization(TACE)
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- up to 60 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion criteria: * age 18 to 75 years ; * HCC confirmed by pathological or clinical diagnosis according to the American Association for the Study of Liver Diseases criteria ; * solitary HCC less than 7cm in diameter or multiple HCC lesions less 5 * the absence of portal/hepatic vein invasion, lymph node involvement and extrahepatic metastases; * lesions visible on ultrasound with a safe path between the lesion and skin; * an Eastern Cooperative Oncology Group performance status of 0-1; * Child-Pugh class A or B cirrhosis. The exclusion criteria : * received any other previous treatment for HCC; * severe coagulation disorders; * evidence of hepatic decompensation including hepatic encephalopathy, ascites as well as esophageal or gastric variceal bleeding; * presence of serious medical comorbidities, including serious dysfunction of the heart or kidney ; * currently had other malignancies in addition to HCC.
References
Publications (0)
Data not yet available
No reference posted for this study.